JAGUAR HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2921 USD | -5.62% |
|
-8.14% | +92.93% |
Presenter SpeechDestiny Buch (Analysts)Hello, and welcome to Ladenburg Thalmann R&D Showcase. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2921
USD
Average target price
0.6
USD
Spread / Average Target
+105.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +92.93% | 80.68M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| -0.23% | 22.25B | |
| -13.14% | 22.09B | |
| -7.66% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- JAGX Stock
- News Jaguar Health, Inc.
- Transcript : Jaguar Health, Inc. - Special Call